Interrupting antiretroviral treatment needs particular careBMJ 2001; 322 doi: https://doi.org/10.1136/bmj.322.7286.616 (Published 10 March 2001) Cite this as: BMJ 2001;322:616
- W A C Sewell, specialist registrar,
- C Mazhude, specialist registrar,
- A Murdin-Geretti, lecturer,
- S Jones, senior pharmacist,
- P J Easterbrook, professor (firstname.lastname@example.org)
- Academic Department of HIV/Genitourinary Medicine, Guy's, King's and St Thomas's School of Medicine, Weston Education Centre, London SE5 9RT
EDITOR—Noble and Kehlet raise an important issue in their editorial about the interruption of drug treatment during the postoperative period.1 We would emphasise the particular problems of drug interruptions in HIV infected patients receiving combination antiretroviral treatment; in these patients the general rule that some drugs are better than none does not apply.
Efavirenz and nevirapine are both non-nucleoside reverse transcriptase inhibitors with long plasma half …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial